What are the recommended dosing regimens for aciclovir in adults and children for herpes simplex virus and varicella‑zoster virus infections, including severe disease, prophylaxis, and adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Aciclovir Dosing

For herpes simplex virus (HSV) infections, aciclovir dosing varies by disease severity and patient age: neonatal CNS/disseminated disease requires 20 mg/kg IV three times daily for 21 days, while non-neonatal CNS/disseminated disease requires 10 mg/kg IV three times daily for 21 days; for varicella-zoster virus (VZV) infections, use 10-15 mg/kg IV three times daily for encephalitis, or 800 mg orally five times daily for herpes zoster in immunocompetent adults. 1, 2, 3

HSV Infections

Neonatal Disease

  • CNS or disseminated disease: 20 mg/kg IV three times daily for 21 days 4, 1, 4
  • Skin, eye, or mouth disease: 20 mg/kg IV three times daily for 14 days 4, 1
  • Critical caveat: Do not discontinue aciclovir in neonates with CNS disease until repeat CSF HSV DNA PCR is negative at days 19-21 of treatment 4, 1

Children (Outside Neonatal Period)

  • CNS or disseminated disease: 10 mg/kg IV three times daily for 21 days 4, 1, 4
  • Moderate-to-severe gingivostomatitis: 5-10 mg/kg IV three times daily, then switch to oral aciclovir when lesions regress; continue until complete healing 1
  • Mild gingivostomatitis: 20 mg/kg oral (max 400 mg/dose) three times daily for 5-10 days 1
  • Genital herpes (children <45 kg): 20 mg/kg oral (max 400 mg/dose) three times daily for 5-14 days 1

Adults and Adolescents

  • Genital herpes (initial episode): 200 mg oral every 4 hours, 5 times daily for 10 days 3
  • Genital herpes (recurrent): 200 mg oral every 4 hours, 5 times daily for 5 days 3
  • Genital herpes (suppressive therapy): 400 mg oral twice daily for up to 12 months 3
  • Alternative for mucocutaneous HSV: Valacyclovir 1 g oral twice daily (adults/adolescents only) 1

VZV Infections

Encephalitis

  • Adults: 10-15 mg/kg IV three times daily for up to 14 days 2
    • Most clinicians use 10 mg/kg dose due to renal toxicity concerns with higher doses 2
    • VZV is less sensitive to aciclovir than HSV, justifying consideration of 15 mg/kg if renal function is normal 2

Herpes Zoster (Shingles)

  • Adults: 800 mg oral every 4 hours, 5 times daily for 7-10 days 3
  • Immunocompromised patients: 10 mg/kg IV every 8 hours 5

Chickenpox (Varicella)

  • Children ≥2 years and ≤40 kg: 20 mg/kg oral four times daily (80 mg/kg/day) for 5 days 3
  • Children >40 kg and adults: 800 mg oral four times daily for 5 days 3
  • Immunocompromised children: IV aciclovir is indicated; oral dosing may be considered at 800 mg five times daily 5, 6

Aciclovir-Resistant HSV

  • Foscarnet: 40 mg/kg IV three times daily OR 60 mg/kg IV twice daily 4, 1
  • Infuse slowly over 2 hours with saline fluid loading to minimize renal toxicity 4

Renal Impairment Adjustments

Dose modifications are mandatory for renal impairment 3:

For 200 mg every 4 hours regimen:

  • CrCl >10 mL/min: 200 mg every 4 hours
  • CrCl 0-10 mL/min: 200 mg every 12 hours

For 400 mg every 12 hours regimen:

  • CrCl >10 mL/min: 400 mg every 12 hours
  • CrCl 0-10 mL/min: 200 mg every 12 hours

For 800 mg every 4 hours regimen:

  • CrCl >25 mL/min: 800 mg every 4 hours
  • CrCl 10-25 mL/min: 800 mg every 8 hours
  • CrCl 0-10 mL/min: 800 mg every 12 hours

Hemodialysis:

  • Administer additional dose after each dialysis session 3

Critical Safety Considerations

Maintain adequate hydration throughout therapy to prevent crystalluria and obstructive nephropathy, which can affect up to 20% of patients, typically manifesting after 4 days of IV therapy 7, 3. Monitor renal function closely, especially with IV administration 4, 3.

Major toxicities include:

  • Neutropenia (particularly in neonates receiving high-dose therapy: 46% in long-term suppressive therapy) 4
  • Nephrotoxicity (6% Grade 3 or higher in neonates) 4
  • Phlebitis, nausea, vomiting, rash 4
  • Rare: hepatitis, bone marrow failure, encephalopathy 7

Avoid concomitant nephrotoxic agents as this increases risk of renal dysfunction and reversible CNS symptoms 3.

Prophylaxis Dosing

HSV Suppression:

  • HIV-infected children with frequent recurrences (>3-6 episodes/year): Oral aciclovir 400 mg twice daily 8
  • Post-neonatal HSV: 300 mg/m² body surface area 2-3 times daily 4

VZV Prophylaxis:

  • Post-auto-HCT: 200 mg oral daily for up to 1 year reduces VZV disease incidence 9

Treatment Timing

Initiate therapy as early as possible for optimal outcomes 10, 7:

  • HSV encephalitis: Mortality decreases to 8% if started within 4 days of symptom onset (vs. 28% overall mortality at 18 months) 10
  • Herpes zoster: Initiate within 72 hours of rash onset 3
  • Chickenpox: Initiate within 24 hours of rash onset 3

References

Research

Antiviral treatment in chickenpox and herpes zoster.

Journal of the American Academy of Dermatology, 1988

Research

[Acyclovir therapy in varicella/zoster diseases in immunocompromised children with cancer].

Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1984

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.